In the high-risk group, altered genes TSC2 and MTOR were highly enriched and these genes played important roles in the activation of PI3K/AKT/mTOR pathways that could lead to the HCC carcinogenesis, progression, and invasion [71]; thus, mTOR and/or PI3K inhibitors had a potential value in treating patients with HCC [72], particularly for the advanced HCC patients in the present study. The gene discussed is AKT1; the disease is hepatocellular carcinoma.